'Mk 0646' presentation slideshows

DISCUSSANT Philip Agop Philip Karmanos Cancer Institute Wayne State University Detroit, MI

Phase I/ II Study of MK-0646 (Dalotuzumab), A Humanized Monoclonal Antibody Against IGF-1R in Combination With Gemcitabine or Gemcitabine + Erlotinib for Advanced Pancreatic Cancer. Javle M , Varadhachary G, Shroff R, Bhosale P, Overman M, Weatherly J, Wolff RA, Abbruzzese J. DISCUSSANT

392 views • 20 slides

A phase I pharmacokinetic and pharmacodynamic study of weekly MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF-1R) monoclonal antibody in patients with advanced solid tumors (Study P001).

374 views • 19 slides